Anne Borgman, MD, has joined the board of directors for NiKang Therapeutics, a biotechnology company focusing on the development of small molecule oncology medicines.
Dr. Borgman joins the board with over two decades of clinical development experience, focusing on oncology and hematology therapeutics. She most recently served as vice president and global therapeutic area lead, hematology-oncology, for Jazz Pharmaceuticals.
Dr. Borgman also served as vice president of clinical research and development at Exelixis and chief medical officer at Hana Biosciences. She is currently on the board of directors for Curis and NextCure, according to a Jan. 18 release from NiKang.